Subscribe

Chi Sheng Pharma & Biotech Co., Ltd (4111.TWO)

TWD30.15 +0.10 (+0.33%)
TW TWO Healthcare Medical - Instruments & Supplies
Address No. 3, Shih Chen Road 30352
Hsinchu, TW
CEO Dongmao Su
Website cscp.com.tw
IPO 2007-12-31
ISIN TW0004111000

Explore sections of this company profile

Description

Chi Sheng Pharma & Biotech Co., Ltd. is a Taiwan-based company actively engaged in the development, production, distribution, and international trade of a diverse range of products. Operating across both domestic and global markets, the company specializes in pharmaceuticals, medical products, cosmetics, health foods, and medical equipment. Its extensive product portfolio covers numerous therapeutic categories, including antibiotics, chemotherapeutic agents, plasma substitutes, amino acid preparations, water nutrients, electrolyte solutions, and vitamins. Additionally, the company provides hepatotropic agents, hormones, adrenal cortical steroids, autonomic nerve agents, antihistamines, antipruritics, antipyretics, analgesics, antitussives, anti-asthmatics, gastro-intestinal preparations, and local anesthetic solutions. Further extending its offerings, Chi Sheng Pharma & Biotech supplies hemodialysis concentrates, peritoneal dialysis solutions, and various other specialized medical items. Beyond medicinal products, the company provides medical devices, fat emulsion products, anesthetics, hemostatic solutions, food products, functional beverages, skincare items, and veterinary medicines. It also offers external solutions such as those for contact lenses, saline, and iodine. The company was founded in 1962 and maintains its headquarters in Hsinchu, Taiwan.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
TWD30.15 +0.10 (+0.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
107.6K
Beta
0.20
Float Shares
46.58M
Free Float %
77.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% +0.50% +3.58% +2.19% +2.88% +3.06% +1.98% +7.28% +39.80% +40.06% +138.23%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
30.15
DCF (Unlevered) 27.63 -8.4%
DCF (Levered) 60.89 +102.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.91
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
4 / 10
Developing
Composite Rating
A+
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Instruments & Supplies: +7.9%
    +18.1% ★ Q1'26: +11.6% (vs Q1'25)
  • ✓
    EPS growth Medical - Instruments & Supplies: +16.3%
    +40.9% ★ Q1'26: +30.9% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    +19.5% ★ Q1'26: -7.6% (vs Q1'25)
  • ✗
    EBIT margin Medical - Instruments & Supplies: +13.5%
    +14.5% ★ Q1'26: +16.2% (vs Q1'25)
  • ✓
    ROIC Medical - Instruments & Supplies: +6.0%
    +16.1% ★ Q1'26: +17.1% (vs Q1'25)
  • ✗
    Share dilution Medical - Instruments & Supplies: +0.1%
    +5.5% Q1'26: +6.1% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    0.18× ★ Q1'26: 0.17× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.07) × ERP
WACC = 97% × Ke + 3% × Kd (4.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 28.35 Current price: 30.15
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana. 		Dec 2031
1 Rev. Ana.
1 EPS Ana. 		Dec 2032
1 Rev. Ana.
1 EPS Ana.
Revenue
984.00M
est.
1.05B
est.
1.14B
est.
1.02B
est: 1.01B (+1.8%)
979.36M
est: 980.00M (-0.1%)
1.02B
est: 1.06B (-3.6%)
1.14B
est: 1.16B (-1.5%)
1.06B
est: 1.22B (-13.3%)
1.17B
est: 1.05B (+10.7%)
1.38B
est: 1.05B (+30.7%)
1.05B
1.05B – 1.05B
+0.0% YoY
1.14B
1.14B – 1.14B
+8.1% YoY
1.01B
1.01B – 1.01B
-11.7% YoY
980.00M
980.00M – 980.00M
-2.5% YoY
1.06B
1.06B – 1.06B
+8.2% YoY
1.16B
1.16B – 1.16B
+9.4% YoY
1.22B
1.22B – 1.22B
+5.4% YoY
EBITDA
177.36M
est.
189.80M
est.
205.21M
est.
180.05M
est: 181.15M (-0.6%)
165.73M
est: 176.64M (-6.2%)
211.94M
est: 191.06M (+10.9%)
236.69M
est: 209.08M (+13.2%)
150.75M
est: 220.44M (-31.6%)
204.56M
est: 195.74M (+4.5%)
271.75M
est: 195.74M (+38.8%)
195.74M
195.74M – 195.74M
+0.0% YoY
211.63M
211.63M – 211.63M
+8.1% YoY
186.82M
186.82M – 186.82M
-11.7% YoY
182.17M
182.17M – 182.17M
-2.5% YoY
197.04M
197.04M – 197.04M
+8.2% YoY
215.63M
215.63M – 215.63M
+9.4% YoY
227.34M
227.34M – 227.34M
+5.4% YoY
EBIT
110.19M
est.
117.92M
est.
127.50M
est.
97.52M
est: 112.55M (-13.3%)
81.59M
est: 109.75M (-25.7%)
132.87M
est: 118.70M (+11.9%)
163.81M
est: 129.90M (+26.1%)
88.79M
est: 136.96M (-35.2%)
139.44M
est: 130.87M (+6.6%)
199.30M
est: 130.87M (+52.3%)
130.87M
130.87M – 130.87M
+0.0% YoY
141.50M
141.50M – 141.50M
+8.1% YoY
124.90M
124.90M – 124.90M
-11.7% YoY
121.80M
121.80M – 121.80M
-2.5% YoY
131.74M
131.74M – 131.74M
+8.2% YoY
144.17M
144.17M – 144.17M
+9.4% YoY
152.00M
152.00M – 152.00M
+5.4% YoY
Net Income
89.79M
est.
92.53M
est.
106.85M
est.
72.45M
est: 63.88M (+13.4%)
59.14M
est: 69.32M (-14.7%)
80.75M
est: 75.63M (+6.8%)
154.01M
est: 132.92M (+15.9%)
68.67M
est: 105.99M (-35.2%)
110.63M
est: 97.60M (+13.3%)
164.28M
est: 92.96M (+76.7%)
92.96M
92.96M – 92.96M
+0.0% YoY
107.35M
107.35M – 107.35M
+15.5% YoY
64.18M
64.18M – 64.18M
-40.2% YoY
69.65M
69.65M – 69.65M
+8.5% YoY
75.98M
75.98M – 75.98M
+9.1% YoY
133.53M
133.53M – 133.53M
+75.8% YoY
106.48M
106.48M – 106.48M
-20.3% YoY
SGA
226.59M
est.
242.48M
est.
262.17M
est.
232.35M
est: 231.43M (+0.4%)
229.15M
est: 225.67M (+1.5%)
218.59M
est: 244.09M (-10.4%)
248.99M
est: 267.12M (-6.8%)
260.22M
est: 281.63M (-7.6%)
280.24M
est: 237.85M (+17.8%)
291.80M
est: 237.85M (+22.7%)
237.85M
237.85M – 237.85M
+0.0% YoY
257.16M
257.16M – 257.16M
+8.1% YoY
227.01M
227.01M – 227.01M
-11.7% YoY
221.36M
221.36M – 221.36M
-2.5% YoY
239.43M
239.43M – 239.43M
+8.2% YoY
262.02M
262.02M – 262.02M
+9.4% YoY
276.25M
276.25M – 276.25M
+5.4% YoY
EPS
1.57
est.
1.62
est.
1.87
est.
1.27
est: 1.12 (+13.9%)
1.04
est: 1.21 (-14.0%)
1.42
est: 1.32 (+7.6%)
2.70
est: 2.32 (+16.4%)
1.21
est: 1.85 (-34.6%)
1.94
est: 1.62 (+20.1%)
2.75
est: 1.54 (+78.8%)
1.54
1.54 – 1.54
+0.0% YoY
1.78
1.78 – 1.78
+15.5% YoY
1.06
1.06 – 1.06
-40.2% YoY
1.15
1.15 – 1.15
+8.5% YoY
1.26
1.26 – 1.26
+9.1% YoY
2.21
2.21 – 2.21
+75.8% YoY
1.76
1.76 – 1.76
-20.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-20 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-19 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-18 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-15 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-14 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-13 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-12 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-11 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-08 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-07 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-06 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-05 A+ 5/5 5/5 4/5 5/5 3/5 4/5 4/5
2026-05-04 A+ 5/5 5/5 4/5 5/5 3/5 4/5 4/5
2026-04-30 A+ 5/5 5/5 4/5 5/5 3/5 4/5 4/5
2026-04-29 A+ 5/5 5/5 4/5 5/5 3/5 4/5 4/5
2026-04-28 A+ 5/5 5/5 4/5 5/5 3/5 4/5 4/5
2026-04-27 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-04-24 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-23 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-22 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-21 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-20 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-17 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-16 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
330.90M
OE per share TTM
5.57
Owner's Yield
18.22%
Maintenance CapEx ratio
6.93%
Maint CapEx / Avg PPE
70.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
2.49M
Shares Outstanding
59.83M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Dongmao Su Chairman & GM — —
Guo Ping Xie Brand Marketing Manager — —
Hui-Zhen Huang Finance Manager & Accounting Supervisor — —
Li Zhu Wei Vice President of Technology & Plant Manager — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Instruments & Supplies